Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction

Overview of attention for article published in JAMA Cardiology, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 6 news outlets
twitter: 121 X users
facebook: 2 Facebook pages

reddit: 1 Redditor
bluesky: 2 Bluesky users

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 7 public wall posts from 2 users.

JAMA Cardiology, 03 Mar 2025

Mavacamten was associated with reductions in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF…

Drgios world, 03 Nov 2024

Mavacamten was associated with reductions in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF…

Drgios world, 03 Nov 2024

Most viewed in the last 7 days from JAMA Cardiology: Study examines the effects of cardiac myosin inhibition with mavacamten in…

Drgios world, 21 Oct 2024

Most viewed in the last 7 days from JAMA Cardiology: Study examines the effects of cardiac myosin inhibition with mavacamten in…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 3 additional Facebook posts.